- Home
- ONCO vs QNRX Comparison
ONCO vs QNRX Comparison
Compare ONCO & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- QNRX
- Stock Information
- Founded
- ONCO 2018
- QNRX 2018
- Country
- ONCO United States
- QNRX United States
- Employees
- ONCO N/A
- QNRX N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- ONCO Health Care
- QNRX Health Care
- Exchange
- ONCO Nasdaq
- QNRX Nasdaq
- Market Cap
- ONCO 4.7M
- QNRX 4.8M
- IPO Year
- ONCO 2022
- QNRX N/A
- Fundamental
- Price
- ONCO $3.60
- QNRX $16.19
- Analyst Decision
- ONCO
- QNRX
- Analyst Count
- ONCO 0
- QNRX 0
- Target Price
- ONCO N/A
- QNRX N/A
- AVG Volume (30 Days)
- ONCO 153.5K
- QNRX 825.4K
- Earning Date
- ONCO 12-09-2025
- QNRX 11-06-2025
- Dividend Yield
- ONCO N/A
- QNRX N/A
- EPS Growth
- ONCO N/A
- QNRX N/A
- EPS
- ONCO N/A
- QNRX N/A
- Revenue
- ONCO $1,326,959.00
- QNRX N/A
- Revenue This Year
- ONCO N/A
- QNRX N/A
- Revenue Next Year
- ONCO N/A
- QNRX N/A
- P/E Ratio
- ONCO N/A
- QNRX N/A
- Revenue Growth
- ONCO N/A
- QNRX N/A
- 52 Week Low
- ONCO $2.45
- QNRX $5.01
- 52 Week High
- ONCO $509.15
- QNRX $48.30
- Technical
- Relative Strength Index (RSI)
- ONCO 54.56
- QNRX 65.94
- Support Level
- ONCO $3.25
- QNRX $12.31
- Resistance Level
- ONCO $4.17
- QNRX $18.99
- Average True Range (ATR)
- ONCO 0.27
- QNRX 4.13
- MACD
- ONCO -0.01
- QNRX 0.64
- Stochastic Oscillator
- ONCO 45.64
- QNRX 27.23
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.